These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 14572532)

  • 1. Why is big Pharma getting out of antibacterial drug discovery?
    Projan SJ
    Curr Opin Microbiol; 2003 Oct; 6(5):427-30. PubMed ID: 14572532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial drug discovery: is small pharma the solution?
    Boggs AF; Miller GH
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial drug discovery: is it all downhill from here?
    Projan SJ; Shlaes DM
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The abandonment of antibacterials: why and wherefore?
    Shlaes DM
    Curr Opin Pharmacol; 2003 Oct; 3(5):470-3. PubMed ID: 14559090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigms for cancer drug discovery.
    Sager JA; Lengauer C
    Cancer Biol Ther; 2003; 2(4):452-5. PubMed ID: 14508120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms for cancer drug discovery.
    Sager JA; Lengauer C
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S178-81. PubMed ID: 14508097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative antibacterial drugs: nothing ventured, nothing gained.
    Stein J
    Expert Opin Investig Drugs; 2005 Feb; 14(2):107-9. PubMed ID: 15757389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics in late clinical development.
    Fernandes P; Martens E
    Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic development: a victim of market forces?
    Tillotson GS
    IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The societal value of pharmaceuticals. Balancing industrial and healthcare policy.
    Grund J
    Pharmacoeconomics; 1996 Jul; 10(1):14-22. PubMed ID: 10160467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the antibacterial resistance crisis.
    Croft AC; D'Antoni AV; Terzulli SL
    Med Sci Monit; 2007 Jun; 13(6):RA103-18. PubMed ID: 17534243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial drug discovery in the 21st century.
    Bush K
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():10-7. PubMed ID: 15522035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.